PURPOSE: Although early intervention is increasingly advocated to prevent and relieve distress in patients with metastatic cancer, the risk factors for such symptoms and their trajectory are not well established. We therefore conducted a longitudinal study to determine the course and predictors of depressive symptoms. PATIENTS AND METHODS: Patients (N = 365) with metastatic gastrointestinal or lung cancer completed measures of physical distress, self-esteem, attachment security, spiritual well-being, social support, hopelessness, and depression at baseline; physical distress, social support, hopelessness, and depression were subsequently assessed at 2-month intervals. RESULTS: Of the sample, 35% reported at least mild depressive symptoms, with 16% reporting moderate to severe depressive symptoms that persisted in at least one third of such individuals. Moderate to severe depressive symptoms were almost three times more common in the final 3 months of life than > or = 1 year before death. Predictors of depressive symptoms included younger age, antidepressant use at baseline, lower self-esteem and spiritual well-being, and greater attachment anxiety, hopelessness, physical burden of illness, and proximity to death. The combination of greater physical suffering and psychosocial vulnerability put individuals at greatest risk for depression. CONCLUSION: Depressive symptoms in advanced cancer patients are relatively common and may arise as a final common pathway of distress in response to psychosocial vulnerabilities, physical suffering, and proximity to death. These findings support the need for an integrated approach to address emotional and physical distress in this population and to determine whether early intervention may prevent depression at the end of life.
PURPOSE: Although early intervention is increasingly advocated to prevent and relieve distress in patients with metastatic cancer, the risk factors for such symptoms and their trajectory are not well established. We therefore conducted a longitudinal study to determine the course and predictors of depressive symptoms. PATIENTS AND METHODS: Patients (N = 365) with metastatic gastrointestinal or lung cancer completed measures of physical distress, self-esteem, attachment security, spiritual well-being, social support, hopelessness, and depression at baseline; physical distress, social support, hopelessness, and depression were subsequently assessed at 2-month intervals. RESULTS: Of the sample, 35% reported at least mild depressive symptoms, with 16% reporting moderate to severe depressive symptoms that persisted in at least one third of such individuals. Moderate to severe depressive symptoms were almost three times more common in the final 3 months of life than > or = 1 year before death. Predictors of depressive symptoms included younger age, antidepressant use at baseline, lower self-esteem and spiritual well-being, and greater attachment anxiety, hopelessness, physical burden of illness, and proximity to death. The combination of greater physical suffering and psychosocial vulnerability put individuals at greatest risk for depression. CONCLUSION:Depressive symptoms in advanced cancerpatients are relatively common and may arise as a final common pathway of distress in response to psychosocial vulnerabilities, physical suffering, and proximity to death. These findings support the need for an integrated approach to address emotional and physical distress in this population and to determine whether early intervention may prevent depression at the end of life.
Authors: J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld Journal: J Neurooncol Date: 2014-08-24 Impact factor: 4.130
Authors: Kelly M Trevino; Paul K Maciejewski; Karen Fasciano; Joseph Greer; Ann Partridge; Elizabeth L Kacel; Susan Block; Holly G Prigerson Journal: J Support Oncol Date: 2012-01-29
Authors: Jill B Hamilton; Allison M Deal; Angelo D Moore; Nakia C Best; Kayoll V Galbraith; Hyman Muss Journal: Oncol Nurs Forum Date: 2013-07 Impact factor: 2.172
Authors: Martin Eichler; Marlene Hechtner; Beatrice Wehler; Roland Buhl; Jan Stratmann; Martin Sebastian; Heinz Schmidberger; Cornelius Kortsik; Ursula Nestle; Hubert Wirtz; Thomas Wehler; Maria Blettner; Susanne Singer Journal: Strahlenther Onkol Date: 2019-07-10 Impact factor: 3.621
Authors: William F Pirl; Joseph A Greer; Lara Traeger; Vicki Jackson; Inga T Lennes; Emily R Gallagher; Pedro Perez-Cruz; Rebecca S Heist; Jennifer S Temel Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Camilla Zimmermann; Dora Yuen; Ashley Mischitelle; Mark D Minden; Joseph M Brandwein; Aaron Schimmer; Lucia Gagliese; Christopher Lo; Anne Rydall; Gary Rodin Journal: Leuk Res Date: 2013-03-11 Impact factor: 3.156
Authors: Marlene H Frost; Paul J Novotny; Mary E Johnson; Matthew M Clark; Jeff A Sloan; Ping Yang Journal: Support Care Cancer Date: 2013-02-19 Impact factor: 3.603
Authors: Christopher Lo; Andrew Calzavara; Paul Kurdyak; Lisa Barbera; Frances Shepherd; Camilla Zimmermann; Malcolm J Moore; Gary Rodin Journal: Can Fam Physician Date: 2013-03 Impact factor: 3.275